William R. Pritchard Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis, Davis, California, 95616, USA.
Department of Medicine & Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, California, 95616, USA.
J Vet Intern Med. 2023 Mar;37(2):660-669. doi: 10.1111/jvim.16673. Epub 2023 Mar 9.
Glucocorticoids are frequently required for management of cough because of inflammatory airway disease (IAD) and airway collapse (AWC).
OBJECTIVES/HYPOTHESIS: To determine the efficacy and feasibility of inhaled administration of corticosteroids in controlling cough in dogs with noninfectious airway disease.
Thirty-six client-owned dogs.
Dogs were prospectively recruited for this placebo-controlled cross-over study. Inflammatory airway disease was diagnosed through bronchoalveolar lavage cytology. Airway collapse was diagnosed through bronchoscopy, or if dogs were unsuitable anesthetic candidates, by crackles on auscultation, radiographic changes in airway diameter, or fluoroscopy. Dogs were randomly assigned to receive placebo or fluticasone propionate for the first 2 weeks of the trial then crossed over to fluticasone. A quality of life (QOL) survey (best score 0, worst score 85) was completed at 0 and 6 weeks. A visual-analog cough survey was submitted at 0, 2, 4, and 6 weeks to assess cough, feasibility, and adverse effects of treatment.
For 32 dogs, QOL score at study end (mean 11.3 ± 9.7) was significantly lower (P < .0001) compared to entry (mean 28.1 ± 14.1), with a median change of 69% in QOL score, indicating improved quality of life. Cough frequency, duration, and severity were significantly (P < .0001) decreased at study end. Feasibility of aerosolized delivery improved with continued use (P = .05) with only 1 dog unable to accept inhaled medication.
This study supports the utility of fluticasone propionate by inhalation in management of cough in dogs with IAD and AWC.
由于炎症性气道疾病（IAD）和气道塌陷（AWC），糖皮质激素经常用于治疗咳嗽。
目的/假设：确定吸入皮质类固醇治疗非传染性气道疾病犬咳嗽的疗效和可行性。
36 只患犬。
这项安慰剂对照交叉研究前瞻性招募了这些犬。通过支气管肺泡灌洗细胞学诊断 IAD。通过支气管镜检查或如果犬不适合麻醉候选者，通过听诊时的爆裂声、气道直径的放射学变化或透视诊断气道塌陷。犬被随机分配接受安慰剂或丙酸氟替卡松治疗试验的前 2 周，然后交叉到丙酸氟替卡松。在 0 和 6 周时完成生活质量（QOL）调查（最佳评分 0，最差评分 85）。在 0、2、4 和 6 周时提交视觉模拟咳嗽调查，以评估咳嗽、治疗的可行性和不良反应。
对于 32 只犬，研究结束时的 QOL 评分（平均值 11.3±9.7）明显低于（P<0.0001）进入时的评分（平均值 28.1±14.1），QOL 评分的中位数变化为 69%，表明生活质量得到改善。咳嗽频率、持续时间和严重程度在研究结束时明显降低（P<0.0001）。随着继续使用，气溶胶输送的可行性得到改善（P=0.05），只有 1 只犬无法接受吸入药物。
这项研究支持吸入丙酸氟替卡松在治疗 IAD 和 AWC 犬咳嗽中的应用。
